Kylie Jenner said her daughter Stormi is allergic to nuts, a year after the 2-year-old was hospitalized with an allergy – Business Insider

sourcePierre Suu/GC Images

A typical day of meals in the life of Kylie Jenner may include celery juice, bone broth, a tuna sandwich, or enchiladas.

But one food thats never on her households menu is nuts because her daughter, Stormi, is allergic to all of them, the 22-year-old Keeping Up With the Kardashians star and owner of Kylie Cosmetics said in a new video for Harpars Bazaar.

Stormi, who turned two last week, was hospitalized for a day last summer due to an allergy an ordeal that Jenner shared on Instagram at the time, without disclosing what exactly the allergy was.

God bless all the moms with sick babies, Jenner wrote on Instagram last summer after Stormi was treated and returned home safely. Im sending so much love and positive energy your way.

Allergies to tree nuts including almonds, Brazil nuts, cashews, hazelnuts, pecans, pistachios, and walnuts -are among the eight most common food allergies, affecting up to 1% of the US population, according to the American Academy of Allergy, Asthma, and Immunology.

An allergy to peanuts, which arent tree nuts, is especially and increasingly common among kids, with the number of affected children tripling between 1997 and 2008, Business Insider previously reported. Today, the US Food and Drug Administration reports about 1 million American children are allergic.

About 30% of people allergic to peanuts are also allergic to tree nuts. It sounds like Stormi is one of them.

Nut allergies of any type can can range from mild to severe, with the most mild cases causing symptoms like a runny nose and the most serious cases resulting in anaphylaxis, which can constrict breathing and be fatal.

Other symptoms can include stomach cramping, indigestion, hives, swelling, and fainting.

The only sure-fire way for a person with a nut allergy to prevent a reaction is to avoid the allergen entirely, but even with strict avoidance, inadvertent exposures can and do occur, Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said in a statement last week.

Thats why the administrations announcement Sunday, that it had approved the first drug, Palforzia, to help treat peanut allergies, was a relief for many parents and medical professionals.

When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy, Marks continued.

There have also been recent advances in peanut allergy prevention in the past several years, with guidelines from the National Institutes of Health updated in 2017 to advise parents on how to introduce at-risk babies to the nuts early on. Previously, parents were simply advised to avoid nuts altogether.

The update was based on strong research finding that the introduction of peanut early in life significantly lowered the risk of developing peanut allergy by age five, Dr. Daniel Rotrosen, director of NIAIDs division of allergy, immunology and transplantation, said in a statement.

Go here to see the original:
Kylie Jenner said her daughter Stormi is allergic to nuts, a year after the 2-year-old was hospitalized with an allergy - Business Insider

Health Promotion and Wellness now accepting applications for peer educators – Penn State News

UNIVERSITY PARK, Pa. Health Promotion and Wellness(HPW), a unit of Penn State Student Affairs, is currently accepting applications for HealthWorks, a peer outreach and education program designed to promote healthy behaviors among students at University Park. Applications for the 2020-21 academic year are currently being accepted through Feb. 28.

HealthWorks offers two unique opportunities for students with an interest in health and wellness to get involved on campus. These opportunities include facilitating one-on-one wellness services with peers and conducting educational workshops and outreach events. During the application process, interested students will have the option to prioritize which opportunity they are most interested in.

Participation in the program involves a three-semester commitment (one semester of training and two semesters of service). For this reason, students who wish to apply must plan to graduate in fall 2021 or later.

Training for the program requires completion of a three-credit course in biobehavioral health, which is offered during the fall semester. Topics covered in the course include alcohol and other drugs, sexual health, nutrition, physical activity, sleep, stress, and other health topics that are relevant to the college population. There are no prerequisites to register for the course.

Upon successful completion of the training course, students complete 45 hours of service each semester. Students participate in one of two sets of service activities: 1) providing free wellness services about stress and time management, physical activity, nutrition, sleep, sexual health, and healthy relationships; or 2) conducting educational workshops and other health promotion initiatives (e.g., Love Your Body Week), staffing outreach tables, assisting with healthy cooking demonstrations, writing content for Healthy Penn State social media, and providing HIV test counseling.

Being a part of HealthWorks has been one of the most rewarding experiences Ive had while here at Penn State," said Christine Woods, a junior majoring in immunology and infectious disease. This unique opportunity allows me to connect with my fellow peers and delve into the world of health and wellness. Beyond that, HealthWorks has taught me marketable skills in leadership, communication and holistic wellness that I am grateful and excited to apply not only during my remaining time at Penn State, but later in my professional career."

For more information about HealthWorks, including an application to apply, visit HPW's HealthWorks webpage.

Here is the original post:
Health Promotion and Wellness now accepting applications for peer educators - Penn State News

Dr. Chen Liu appointed the Brady Professor of Pathology – Yale News

Dr. Chen Liu

Dr. Chen Liu, recently named as the Anthony N. Brady Professor of Pathology, is an expert in viral hepatitis, liver cancer immunotherapy, graft-versus-host disease, and cancer epigenetics. His appointment will be effective March 1.

In November, Liu was named chair of the Department of Pathology at Yale School of Medicine and chief of pathology at Yale New Haven Hospital, also effective March 1. He is currently professor and chair of pathology, immunology, and laboratory medicine at New Jersey Medical School and at Robert Wood Johnson (RWJ) Medical School at Rutgers University, where he chairs the Center for Dermatology. He also is chief of service at University Hospital in Newark and RWJ University Hospital in New Brunswick and chief of the Division of Oncological Pathology at the Rutgers Cancer Institute of New Jersey.

Lius research team has made significant contributions to the understanding of virus or alcohol-induced carcinogenesis, cancer biomarker discovery and novel therapies using small molecules and immunotherapy. His research work has been continuously funded by the National Institutes of Health and other agencies. He has published more than 240 peer-reviewed articles and book chapters, and holds five patents and pending applications. As a gastrointestinal and liver pathologist, he provides expert consultations for both adult and pediatric patients.

After obtaining his medical degree at Tong Liao Medical College at Inner Mongolia University of Nationality and completing his postgraduate training at Peking Union Medical College in China, Liu received his Ph.D. in pathology from the University of Pennsylvania School of Medicine. He completed his residency in anatomical and clinical pathology at Medical College of Pennsylvania, held an oncological pathology fellowship at M.D. Anderson Cancer Hospital, and had postdoctoral training at Scripps Clinic. Before his appointments at Rutgers in 2015, he was professor and vice chair of pathology, immunology, and laboratory medicine at the University of Florida, where he also held an endowed chair in gastrointestinal and liver research.

View post:
Dr. Chen Liu appointed the Brady Professor of Pathology - Yale News

Abu-Amer named J. Albert Key Professor – Washington University School of Medicine in St. Louis

Visit the News Hub

Professorship endows research into causes of inflammation and related skeletal problems

At the installation of Yousef Abu-Amer, PhD, as the J. Albert Key Professor are (from left) David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine and the Spencer T. and Ann W. Olin Distinguished Professor; Regis J. OKeefe, MD, PhD, the Fred C. Reynolds Professor and head of the Department of Orthopaedic Surgery; Abu-Amer; and Chancellor Andrew D. Martin.

Yousef Abu-Amer, PhD, a leading expert in inflammatory joint disease and bone loss, has been named the inaugural Dr. J. Albert Key Professor at Washington University School of Medicine in St. Louis.

The new professorship was created through the philanthropic legacy of J. Albert Key, MD, who chaired the Division of Orthopaedic Surgery at Washington University from 1930 until his death in 1955. Another Washington University professorship named for Key, the J. Albert Key Distinguished Professorship in Orthopaedic Surgery, is held by spine specialist Keith H. Bridwell, MD.

Abu-Amer was installed by Chancellor Andrew D. Martin and David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean of the School of Medicine and the Spencer T. and Ann W. Olin Distinguished Professor.

Through Dr. Keys philanthropic legacy and the support of the Department of Orthopaedic Surgery, this professorship allows us to continue to advance research and education in orthopedics while honoring and paying tribute to an esteemed surgeon and leader who also relished his role as a teacher and mentor, Martin said.

Said Perlmutter: Dr. Keys work as a physician-scientist investigating the roots of arthritis, disorders of the hip joint and deterioration of bone laid the groundwork for what has become an outstanding orthopedics department at the School of Medicine, making progress in both clinical injury management and research into the causes of bone and joint disorders. I believe he would have been proud to support the very important research Dr. Abu-Amer has advanced in their shared field.

Estimates indicate more than 60 million Americans suffer from inflammatory joint diseases and that arthritis is the leading cause of disability in the United States. Abu-Amer studies some of the most devastating complications of inflammatory arthritis: joint erosion and excessive bone loss associated with advanced and late stages of the disease. He is interested in deciphering the molecular mechanisms at the interface of inflammation and skeletal tissue to help doctors pinpoint therapeutic interventions.

Yousef is a leader in the investigation of inflammation and its molecular signatures in immune cells, bone cells and cartilage cells, said Regis J. OKeefe, MD, PhD, the Fred C. Reynolds Professor and head of the Department of Orthopaedic Surgery. He is working to improve our understanding of bone and joint degeneration and to develop better preventive and therapeutic responses. His work is significantly advancing our understanding of the relationship between inflammatory molecular pathways and major events, such as joint failure, that can require extensive surgical interventions.

Abu-Amer is a fellow of the American Society for Bone and Mineral Research and a former member of the organizations policy and publication committees. In 2002, he received the Kappa Delta Young Investigator Award from the American Academy of Orthopedic Surgeons. He is a standing member of the National Institutes of Healths (NIH) Skeletal Biology Structure and Regeneration Study Section and previously was a grant reviewer for NASA, the Department of Veterans Affairs, the Department of Defense and the Arthritis Foundation, and other funding agencies. He has had continuous funding from the NIH since 1999 and from Shriners Hospitals for Children since 2002.

Abu-Amer earned his bachelors and masters degrees and doctorate from the Hebrew University in Jerusalem. He completed his postdoctoral fellowship training in the Department of Pathology & Immunology at Washington University before joining the faculty in 1999. Abu-Amer also is a professor of cell biology & physiology, associate director of the Musculoskeletal Research Center and director of the Animal Models of Joint Injury and Disease Core at the School of Medicine.

Key graduated from the Johns Hopkins University School of Medicine in 1918 and trained in surgery and orthopedics at Boston Childrens Hospital and Massachusetts General Hospital in Boston. In 1926, Washington University recruited him to become director of research at what was previously known as St. Louis Shriners Hospital for Crippled Children. In 1930, he became head of orthopedic surgery, and in 1945, he established the School of Medicines orthopedic surgery residency.

Several awards bear his name, including the Mid-America Orthopaedic Associations J. Albert Key Award for Resident Research and the J. Albert Key Prize for Excellence in Medical Writing. At Washington University, the J. Albert Key Memorial Orthopaedic Library was established in his honor, and in 1989, Asa C. Jones, MD, and his wife, Dorothy, created the J. Albert Key Distinguished Professorship in Orthopaedic Surgery. Asa C. Jones, an orthopedic surgeon and 1942 graduate of the School of Medicine, was mentored by Key.

Key co-authored six editions of the book Management of Fractures, Dislocations and Sprains, at one time the definitive text on orthopedic trauma. He also was named president of the American Orthopaedic Association in 1946 and of the Orthopaedic Research Society in 1955.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

The rest is here:
Abu-Amer named J. Albert Key Professor - Washington University School of Medicine in St. Louis

New success in treating allergies to peanuts and other foods – Science News for Students

Ten years ago at a kindergarten party, Isaac Judy took abite of a peanut-butter cookie. It tasted weird to him, so he spit it out. Hivessoon appeared on his face. His lips also began to swell. When his dad came topick him up, Isaac was coughing and wheezing. Riding in the car to the otherside of St. Louis, Mo., where they lived, Isaac fell asleep or so it seemed.

When Isaacs mother saw what was happening, she suspectedsomething more serious. He hadnt fallen asleep. He lost consciousness, JaelitheJudy explains. After a trip to the emergency room, her five-year-old recovered.But doctors confirmed her hunch: Isaac has a peanut allergy.

Just a few generations ago, hardly anyone talked about foodallergies. But over the past two decades, childhood food allergies in the UnitedStates have more than doubled. A little more than a year ago, a studyin Pediatrics reported that 7.6 percent of U.S. kids under age 18 havefood allergies. Thats almost 8 million youth about two students per classroom.And its much more than a childhood issue. Surprisingly, a studylast year in JAMA Network Open found that nearly 11 percent ofadults have food allergies, too. More than one in every four of them said they hadnot been allergic to foods as children.

These days nearly everyone has come across a family member orperson who has been touched by food allergies, or has one themselves,says Tamara Hubbard. She works in the suburbs of Chicago, Ill., as a licensedcounselor. Hubbard and a growing number of counselorsare helping families through the stress of managing food allergies.

For years, doctors have told families theres nothing they can do but avoid the trigger food or inject a fast-acting medication called epinephrine (Ep-ih-NEF-rinn) to stop a severe reaction. But researchers are learning more about why some people overreact to certain foods. And new treatments are emerging. Late last month, the first treatment for peanut allergy earned approval from the U.S. Food and Drug Administration. Another could do so within a year or so. Scientists also are continuing to develop and test other ways to treat food allergies.

Weekly updates for inquiring minds of every age, delivered to your inbox

Allergic reactions occur when the immune system overreacts.Normally immune cells help fight bacteria, viruses and other pathogens. Yetsome peoples immune systems also react to harmless stuff like pollen or mold or peanuts, milk or other foods.

Such run-ins trigger a release of histamine (HIS-tuh-meen) and other chemicals. These molecules get the ball rolling for an allergic reaction, explains Tina Sindher. She works as an allergist at Stanford University School of Medicine in Palo Alto, Calif.

During an allergic reaction, someone may get itchy anddevelop hives. If the reaction worsens, the person might cough, wheeze andsuffer a whole-body reaction known as anaphylaxis(An-uh-fuh-LAX-iss). Thats what happened to Isaac and to Shea Tritts son,Gaines, in Abingdon, Va.

Gaines peanut allergy surfaced in the fall of 2012. At thetime, he was a baby and his diagnosis put the whole family on edge. For thenext few years he never trick-or-treated. He never went to a birthday party. Iwas scared to put him in preschool, says Tritt. My husband and I had a lot ofstress because he could tell I wasnt letting Gaines do normal things. So wewould argue.

Even Gaines older sister got nervous. If she went to aparty, she worried about bringing back traces of peanut-containing treats that mightsicken her brother, Tritt recalls. Living in such constant vigilance can be emotionallydraining for families with food allergies.

Anxious and desperate, Tritt wondered if her son would outgrow his allergies, and how she could ever find out. I became obsessed with information anything I could do to get us out of this situation, she says.

One day, Tritt saw a TV interview with David Stukus. Hes an allergist at Nationwide Childrens Hospital in Columbus, Ohio. Stukus saw that many patients with food allergy are fearful. They often are confused because theyre not getting the facts they need. So Stukus opened a Twitter account to spread evidence-based information. Tritt took note.

Looking at her sons blood-test results, year after year, Trittsuspected his immune response to peanuts was lessening. However, blood testscannot give a clear yes or no. These tests detect specialized immuneproteins. They are called IgE antibodies. These molecules trigger allergicreactions. But IgE levels only indicate that someone is sensitive to a certainfood. They cannot predict whether that person will react if they eat it. ProvingGaines had outgrown his peanut allergy would require an oral food challenge. And that would require that the patient eatincreasing amounts of the food while a doctor watches for allergicreactions.

Trouble is, Tritt could not find a local allergist toperform the food challenge. This procedure needs extra time and staff. It also runsa risk of triggering anaphylaxis. So, many clinics wont offer it unless apatients blood results are low low enough to suggest they would tolerate thefood. Gaines numbers had steadily dropped over the years but were still a tadtoo high.

For about half of people with peanut allergies, a bite or two of the wrong food typically contains enough peanut protein to trigger a reaction, notes Brian Vickery. He is a pediatric allergist at Emory University in Atlanta, Ga. For these people, he says, 100 milligrams (0.004 ounce) of peanut protein, or about one-third of a peanut kernel, can set off such a reaction.

Vickery used to work at Aimmune Therapeutics. ThisCalifornia company is developing a treatment for peanut allergy. It is calledoral immunotherapy, or OIT for short. The procedure involves each day eating awee bit of peanut protein pre-measured into capsules. The capsule dose goesup every few weeks over a period of months. If the treatment works, it canraise the immune systems threshold for the food. That means it would take moreof the food to trigger an allergic reaction. In other words, its possible for theperson to become bite-proof.

Aimmune tested its capsules or a dummy version called a placebo in 551 children and teens with peanut allergies. The starting dose was half a milligram (0.00002 ounce) of peanut protein. (One peanut contains 600 times that much.) Over a six-month period, the daily dose went up to 300 milligrams (0.01 ounce), or about one peanuts worth. And each day for six more months, participants had to continue eating that much.

During the study, many participants experienced allergicreactions to the peanut pills. Forty-five quit because of these unpleasantsymptoms. But among those who finished the study, two-thirds of the treatedgroup became bite-proof. After about a year, they could safely eat roughlytwo peanuts. Theyre still careful about avoiding peanuts, saysVickery. But it provides that additional margin of safety.

Those results appearedin the November 2018 New England Journal of Medicine.

Based on these and other findings, the FDA approved thosepeanut capsules on January 31.

Over the past decade and prior to the FDA approval, a small number of allergists had already started offering OIT using store-bought foods. Tritt found one such clinic several hours away. However, that clinic was not willing to give her son a peanut challenge to confirm whether he still was allergic.

Tritt didnt want to sign her son up for a long, costlytreatment if he might in fact be outgrowing his allergy.But they couldntknow for sure without the gold-standard test, that oral food challenge.

She discussed her dilemma with Stukus on Twitter. ReviewingGaines blood-test results, Stukus agreed to conduct the food challenge. Justbefore Gaines started kindergarten, his family travelled from Virginia to thedoctors clinic in Ohio. It was a nine-hour drive.

Gaines started the challenge with a small, laughableamount of peanut butter, Tritt recalls. Fifteen minutes later, he ate a bitmore. Then some more. Over several hours he chomped a dozen Reeses peanutbutter cups. And he never reacted.

The test proved Gaines had outgrown his allergy. That makeshim one of the lucky few. Many children outgrow some food allergies by the timethey enter school. But eight out of every 10 kids with allergies to peanuts or treenuts will remain allergic.

Gian Lagemann, a high school senior in Saratoga, Calif., isallergic to 11 kinds of nuts, including peanuts (which actually is not a nut; its a legume). When hestarted kindergarten, his mother brought no nuts allowed signs to theclassroom. She asked other parents to tell her whenever they brought in food so she could make sure it was safe for Gian. Every day Gian ate his lunch at adesignated peanut-free table.

Several years ago, Gians mom told her son about a peanutOIT trial. The study was starting nearby at Stanford University. For most ofmy life, I havent been able to eat things where the ingredient labels say maycontain peanuts or processed in a facility with peanuts, Gian says. Onceshe explained that [after the trial] Id be able to eat those foods, I waspretty happy. I was sold.

At the start of the trial, his family bought a bag of peanut flour. For about six months, Gian took his dose each day after dinner. He doesnt like the taste of peanuts. So he often mixed his dose into a spoonful of chocolate ice cream. The dose started at 1.3 milligrams of peanut protein (about 1/200th the amount in a peanut). Over the six-month trial it went up to 240 milligrams (0.008 ounce, or a little less than one peanuts worth).

More broadly, some 8,000 U.S. patients havetried such an oral therapy. Typically, about one in five will withdraw becauseof side effects or anxiety. Completing such a trial takes focusand discipline like playing sports. But, Gian recalls, They told us withevery dose we took, our body was just going to get stronger.

Participants also learned to expect some allergic reactions.If youre going to build your immune muscle against a food allergy, you knowyoure going to have a little ache during the process, says Kari Nadeau. ThisStanford allergist was a leader of the trial.

Gian felt a few such responses during the study. My throat would feel a little tight for 15 minutes, he says. But after that, it was fine. So he persevered. And it paid off. When the trial ended, he could eat a full peanut without having an allergic reaction. That means Gian now can safely eat candy with labels warning theyre made in facilities that process nuts. I was able to try Kit Kats for the first time, and Milky Ways, Gian says.

Two years ago, Isaac also tried this oral peanuttherapy. At the time, he was 13. But his experiences were quite different.During the treatment he suffered sinus and gastrointestinal troubles. He alsohad an anaphylactic reaction. Six months in, Isaac dropped out. He quit becausehe had developed an immune condition called eosinophilicesophagitis (Ee-oh-sin-oh-FILL-ick Ee-SOF-uh-JY-tis). The oral therapy triggersit in a small share of people.

And theres something else to keep in mind:People could lose their desensitization to peanut once they end the oraltherapy. That finding was confirmed in a 2019 study by Nadeaus team. Formany people, effective treatment might have to continue long-term.

Some people have taken part in research trialstesting a different treatment for peanut allergy a skin patch. Instead ofeating bits of peanut by mouth, patients every day stick a coin-sized disc ontotheir back or upper arm. Each disc contains a quarter-milligram of peanutprotein. Thats about a thousandth as much as whats in a peanut. (Bycomparison, Aimmunes capsules start with twice that much. Over months,patients then take doses that increase to 1, 10, 20, 100 and 300 milligrams.)From the patch, peanut proteins seep through the skin but do not enter theblood. Peanut patches are therefore less likely to cause anaphylaxis than is theoral therapy.

DBV Technologies in France makes the patch. This company conducted a year-long trial of its product in 356 children with peanut allergies. Nine in every 10 participants finished the trial. The most common side effect was a skin rash at the patch site. However, this trial didnt work as well as the company had hoped. By the end of the study, only a little more than one in every three patients treated could safely eat the exit dose of one to three peanuts. The study leaders reported their findings in the March 12, 2019 Journal of the American Medical Association.

Still, the patch has worked wonders forsome. In 2012, Sharon Wong was desperate. Her sons allergies to peanuts andtree nuts had intensified to an alarming degree. Once during a shopping trip,he went into a coughing fit while walking past a batch of freshly baked walnutcookies. At a restaurant buffet, he started vomiting after merely looking at asteamy tray of pesto pasta. (Pesto is made with pine nuts.)

It was really awful, recalls Wong. Wecannot control the air he breathes. But we didnt want to keep him confined athome. We wanted him to be able to go shopping, to go down the street, to go tofriends homes and not stress about his allergies.

That year she enrolled her son, then nine years old, in an earlier-stage peanut patch trial in the San Francisco Bay area of California. At first, it took just 1/240th of a peanut to trigger an allergic reaction. After two years on the patch, he could tolerate about six peanuts.

We feel more comfortable about travelinglonger distances and dining in restaurants with precautions in place, Wongwrote in a blog about the patch trial. Each mini-success gives usconfidence and improves our quality of life. My son is happier and healthier.

In August, the FDA plans to review data on the peanut patch and recommend if it should be approved. DBV Technologies is also researching and developing patches to treat milk and egg allergies. And as for oral therapies, Aimmune recently started a new trial for its egg-allergy treatment. The company is also developing an oral therapy for walnut allergy.

Scientists are studying other related approaches, too. One is an immune therapy that uses liquid droplets containing allergens. These are placed under the tongue rather than swallowed directly. Edwin Kim, an allergist at the University of North Carolina School of Medicine, in Chapel Hill, led one study of children treated for three to five years with this sublingual therapy. All had peanut allergies. Of the 37 kids who completed the study, two in every three could now consume 750 milligrams (0.03 ounce) or more of the peanut allergen. Kim, whose center has helped conduct studies for DBV and Aimmune (among other companies), reported the findings last November in the Journal of Allergy and Clinical Immunology.

Additional experimental treatments block other parts of theimmune response to allergens. Some act together with oral therapy, allowingfewer allergic reactions during therapy. Others supply helpful gut microbesthat seem to guard against food allergies. And one company is developing atoothpaste to treat peanut allergy.

In the end, each family must decide whether to seek anemerging treatment or stick with just avoiding exposure to the sensitizingfoods. Treatments require diligence. Theyre not yet widely available. And theydont always work. But if the allergy is unbearable, trying a new treatment mightprove worth the time and risk. Clearly, concludes Stukus, the Ohio doctor, food-allergymanagement is not one-size-fits-all.

See the original post:
New success in treating allergies to peanuts and other foods - Science News for Students

Dr. Yancopoulos and Regeneron Working on Coronavirus Treatment – The National Herald

By TNH Staff February 6, 2020

Dr. George D. Yancopoulos, Regeneron President and Chief Scientific Officer, spoke at the St. Demetrios Graduation in Astoria. (Photo: TNH/Kostas Bej)

WASHINGTON, DC The United States has announced that it will work with the drug company Regeneron to develop an effective treatment for the new Chinese coronavirus, using drugs that have been tested to fight the Ebola virus.

Many different therapies are currently being tested for the new coronavirus (2019-nCoV), three of which are at an advanced stage: a drug administered to HIV carriers (Kaletra), a combination of drugs used for the coronavirus MERS (antivirals and immunotherapy) and a U.S. company Gilead antivirus that had been previously tested for Ebola virus.

The partnership between the U.S. government and Regeneron concerns a treatment based on monoclonal antibodies. A public-private partnership, like the one we have with Regeneron since 2014, allows us to respond quickly to new global health threats, said Rick Bright, a U.S. health official.

Monoclonal antibodies are copies of one type of antibody prepared in the laboratory. They are a kind of immunotherapy. They attach to certain proteins of the virus and neutralize its ability to invade human cells.

Regeneron has created the cocktail REGN-EB3, which consists of three monoclonal antibodies and last year significantly improved the survival rate of patients infected with Ebola virus in the Congo. The company has also developed a treatment for Middle Eastern Respiratory Syndrome (MERS).

The convincing results of our experimental treatment for Ebola last year showed Regenerons ability to respond quickly to new outbreaks, explained Greek-American Dr. George Yancopoulos, Regenerons President and chief scientific officer.

The cure for the new coronavirus may eventually include many types of medication.

The coronavirus epidemic is likely to have an impact on U.S. supply chains, but the consequences are unlikely to be disastrous, White House financial adviser Larry Cadlow said in an interview with Fox Business, ANA-MPA reported.

Its not a disaster, Cadlow said, adding that weve had it in the past and I just think the impact is minimal, ANA-MPA reported.

The American-born Dr.Yancopoulos,one of the nations leading scientists and head of one of the largest pharmaceutical companies listed on the New York Stock Exchange, grew up inWoodside, Queens. He was the valedictorian of both theBronx High School of ScienceandColumbia University, and received his MD and PhD degrees in 1987 from Columbia Universitys College of Physicians & Surgeons.Yancopoulosworked in the field of molecular immunology at Columbia University with Dr. Fred Alt, and received the Lucille P. Markey Scholar Award for his efforts. In 1989, he left his academic career and became the founding scientist for Regeneron withLeonard Schleifer. Among his honors,Yancopouloswas awarded Columbia Universitys Stevens Triennial Prize for Research and its University Medal of Excellence for Distinguished Achievement. In 2004, he was elected to the National Academy of Sciences and the American Academy of Arts and Sciences.

More:
Dr. Yancopoulos and Regeneron Working on Coronavirus Treatment - The National Herald

Wisconsin Experiment Heading To Space Could Someday Benefit Your Gut Health – WUWM

A Wisconsin experiment is heading to the International Space Station. The results could help keep a good balance in your gut. WUWM's Chuck Quirmbach reports.

A rocket scheduled to go to the International Space Station on Sunday will carry a Wisconsin experiment that could help in the fight against bacteria that resist antibiotics. The research may also assist future astronauts and other space travelers.

Scientists have known for about a century that viruses called phages can destroy harmful bacteria without large-scale killing of cells or beneficial bacteria in the human body. But soon after that discovery, the development ofpenicillin and other antibiotic drugs dampened the idea of making more use of phages. That's changed in recent years, as more bacteria have grown resistant to antibiotics.

On Sunday afternoon, the virus research moves off the Earth and into space. Weather permitting, a rocket will be launched from a NASA facility in Virginia. Its a re-supply mission to the space station. But the rocket will also carry material for several experiments. That includesfrozen tubes of bacteria and phages for research spearheaded by UW-Madison Biochemistry assistant professor Vatsan Raman.

On a recent NASA conference call, Raman said phages are the most abundant living entity.

"It's estimated that for every bacterium on Earth, there's approximately 10 or more phages. And when the phages find their bacterial host, they inject their DNA into the bacteria, make many, many copies and sometimes kill the host," Raman said.

In humans, this interaction of micro-organisms takes place in what scientists call the microbiome. Raman says probably the biggest reservoir of phages and bacteria is the gut, or the small and large intestines. He says when there isn't the right balance of the microbes you may feel ill.

It can often lead to pathogenesis, which means you can have an infective species kind of take over the population, which is obviously not good. Sometimes you can have digestive disorders because your microbiome plays an important role in processing your diet. So, maintaining a healthy microbiome, where you have diverse species present is absolutely essential for health," Raman said.

On the International Space Station, he says astronauts will conduct experiments looking at how the microgravity and radiation not found on Earth may affect the virus-bacteria interaction. Weaker gravity could change how often phages bump into bacteria. Raman says the radiation in space, sometimes high energy cosmic rays, could lead to mutation of DNA.

"Which means, the frequency phages and bacteria might mutate is perhaps higher in space than on Earth. Which leads to the question: what happens then? Do the phages acquire new functions? Do they lose existing functions? Does the bacteria acquire new functions? Does it lose existing function? Raman said.

With the U.S. planning to send more astronauts into space in the coming decades, and President Donald Trump even viewing the planned Space Force as a branch of the military, the U.S. Defense Threat Reduction Agency is funding the phage experiment.

A Texas-based biotechnology corporation, Rhodium Scientific,is also interested in the results. Rhodium's Heath Mills is co-investigator on the project known as Phage Evolution. Mills says imagine being able to target a phage toward a pathogen, or disease-causing micro-organism.

"You're now looking at a highly-focused mechanism to alleviate a troublesome, pathogenic, harmful bacteria, while leaving the rest of that microbiome intact. The problem with current anti-microbials, antibiotics, is that they destroy a vast swath of that microbiome, of which now you need to have replacements, which you need to go back in and rebuild over time," Mills said.

Mills says better targeting could help astronauts and future space tourists,as well as most of us who will never leave the ground.

After the experiments on the International Space Station, samples will come back and be compared to results found on Earth.

Do you have a question about innovation in Wisconsin that you'd like WUWM's Chuck Quirmbach to explore? Submit it below.

_

Read the rest here:
Wisconsin Experiment Heading To Space Could Someday Benefit Your Gut Health - WUWM

Early Career Award Advances Work on Computational Models of Proteins – University of Arkansas Newswire

Photo by University Relations

Mahmoud Moradi, University of Arkansas.

FAYETTEVILLE, Ark. Chemist Mahmoud Moradi has received a $650,000 National Science Foundation Faculty Early Career Development award to advance his work modeling the function of proteins at the molecular level, which will deepen our understanding of disease and improve drug design.

Moradis research lies at the intersection of biology, physics, chemistry, mathematics, statistics and computer science. An assistant professor in the Department of Chemistry and Biochemistry, he develops biomolecular simulations and computational theories that explain how proteins function at the molecular level. The theories improve geometric models to describe how proteins change their shape and how these changes affect a protein's behavior.

Proteins are considered the workhorse molecules of cells. They are responsible for nearly all tasks in cellular life, including product manufacture, waste cleanup and routine maintenance. Some proteins transport materials and information between the cell and its environment, a vital task for the survival and normal function of the cell. Any disorder in protein function can result in disease. Therefore, the study of protein function is necessary for understanding the molecular basis of disease.

Recent advances in supercomputing technology has enabled us to simulate complex biomolecular systems that might contain millions of atoms, Moradi said.

By allowing us to visualize the behavior of the proteins and other biomolecules at the molecular level, these simulations are helpful not only in understanding their workings but also in designing therapeutics to manipulate their behavior when they dont function right.

Theoreticians have been trying to come up with shortcuts to accelerate the computer simulations of protein behavior without compromising reliability. These shortcuts, called enhanced sampling techniques, are based on Euclidean geometry, which is embedded in conventional statistical mechanics.

Moradis project improves enhanced sampling techniques by incorporating a more general and accurate geometry, known as Riemannian geometry. Riemannian geometry allows the intrinsic protein space to be curved, somewhat similarmathematicallyto Einstein's general relativity theory, where gravity curves, or warps, spacetime.

The Faculty Early Career Development Program, also called CAREER, is the NSFs most prestigious award in support of early-career faculty who have the potential to serve as academic role models in research and education and to advance the mission of their department or organization. Research by early-career faculty build a firm foundation for a lifetime of leadership integrating education and research. Moradis award is part of the Chemical Theory, Models and Computational Methods program in the Division of Chemistry.

About the University of Arkansas: The University of Arkansas provides an internationally competitive education for undergraduate and graduate students in more than 200 academic programs. The university contributes new knowledge, economic development, basic and applied research, and creative activity while also providing service to academic and professional disciplines. The Carnegie Foundation classifies the University of Arkansas among fewer than 2.7 percent of universities in America that have the highest level of research activity. U.S. News & World Report ranks the University of Arkansas among its top American public research universities. Founded in 1871, the University of Arkansas comprises 10 colleges and schools and maintains a low student-to-faculty ratio that promotes personal attention and close mentoring.

See the original post here:
Early Career Award Advances Work on Computational Models of Proteins - University of Arkansas Newswire

Toxic Protein, Linked to Alzheimer’s and Other Neurodegenerative Diseases, Exposed in New Detail – P&T Community

NEW YORK, Feb. 6, 2020 /PRNewswire/ -- The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases. But scientists have struggled to understand exactly how tau converts from its normal, functional form into a misfolded, harmful one. Now, researchers at Columbia University's Zuckerman Institute and Mayo Clinic in Florida have used cutting-edge technologies to see tau in unprecedented detail. By analyzing brain tissue from patients, this research team has revealed that modifications to the tau protein may influence the different ways it can misfold in a person's brain cells. These differences are closely linked to the type of neurodegenerative disease that will develop and how quickly that disease will spread throughout the brain.

The study, published today in Cell, employed two complementary techniques to map the structure of tau and decipher the effects of additional molecules, called post-translational modifications (PTMs), on its surface. These new structural insights could accelerate the fight against neurodegenerative diseases, by helping researchers identify new biomarkers that detect these disorders before symptoms arise and design new drugs that target specific PTMs, preventing the onset of disease before it wreaks havoc on the brain.

"Tau has long been a protein of significant interest due to its prevalence in disease," said Anthony Fitzpatrick, PhD, a Principal Investigator at Columbia's Mortimer B. Zuckerman Mind Brain Behavior Institute who led the study. "In today's publication, we lay out compelling evidence that PTMs play an important structural role in tauopathies, the collection of neurodegenerative diseases characterized by toxic buildup of misfolded tau."

No two tauopathies are exactly alike. Each affects different parts of the brain even different cell types which can lead to different symptoms. Alzheimer's, for example, arises in the hippocampus, and so affects memory. Chronic traumatic encephalopathy, a disorder most often seen in survivors of traumatic brain injury, can lead to problems with movement, memory or emotion, depending on which areas of the brain are affected.

Scientists have used traditional imaging techniques to find clues to how tangles of tau, comprised of individual fibers, or filaments, are implicated in these diseases. But painting a complete picture has proven difficult.

"The brains of patients with neurodegenerative diseases are easy to identify: entire sections have been eaten away, replaced by large clumps and tangles of misfolded proteins like tau," said Tamta Arakhamia, an undergraduate at Columbia's School of General Studies, a research assistant in the Fitzpatrick lab and the paper's co-first author. "However, tau filaments are 10,000 times thinner than the width of a human hair, making them extraordinarily difficult to study in detail."

To address this challenge, Dr. Fitzpatrick recently pioneered the use of cryo-electron microscopy, or cryo-EM, to visualize individual tau filaments from diseased human brain tissue. Cryo-EM is a Nobel Prize-winning technology developed, in part, by researchers at Columbia University. Cryo-EM images samples using a beam of electrons and has proven indispensable for investigations into extremely small biological structures. Using cryo-EM, Dr. Fitzpatrick's team has reconstructed the structures of tau filaments, providing new insights into how they form, grow, and spread throughout the brain.

For all its ability to provide highly detailed snapshots of proteins, cryo-EM has limits. To overcome these limits, Dr. Fitzpatrick and his team to paired it with a second technology: mass spectrometry.

"Cryo-EM does not provide a complete picture because it cannot fully recognize the microscopic PTMs on tau's surface," said Christina Lee, an undergraduate student at Columbia College, a research assistant in the Fitzpatrick lab and the paper's co-first author. "But mass spectrometry can pinpoint the chemical composition of PTMs on the surface of tau."

Working with co-corresponding author Leonard Petrucelli, PhD, Ralph B. and Ruth K. Abrams Professor of Neuroscience at Mayo Clinic in Florida, and Nicholas Seyfried, PhD, professor of biochemistry at Emory University School of Medicine, the researchers used cryo-EM and mass spectrometry to analyze the brain tissue from patients diagnosed with two tauopathies: Alzheimer's disease and corticobasal degeneration, or CBD. CBD is a rare but extremely aggressive tauopathy, affecting only one in every 10,000 people. Unlike Alzheimer's, which is thought to arise due to a number of factors including tau, CBD is primarily associated with misbehaving tau proteins.

"Studying a primary tauopathy like CBD helps us to figure out how tau becomes toxic to brain cells," said Dr. Petrucelli. "We hope to extrapolate that knowledge to secondary tauopathies, such as Alzheimer's disease."

The scientists' analysis of brain tissue samples revealed several key insights. Most notably, the researchers found that cross-talk between PTMs on the surface of tau influences the structure of the tau filaments, contributing to differences in tau filaments observed across the various tauopathies and even variations from patient to patient.

"Collectively, these results suggest that PTMs may not only be serving as markers on the proteins' surface, but are actually influencing the behavior of tau," said Dr. Fitzpatrick, who is also an assistant professor of biochemistry and molecular biophysics at Columbia's Vagelos College of Physicians and Surgeons.

Moving forward, Dr. Fitzpatrick and his team plan to expand this work to other tauopathies. Today's findings on Alzheimer's and CBD hold immense promise for the field, particularly in the development of new disease models such as lab-grown organoids, or mini-brains that may serve to accurately recapitulate what is actually happening in the brains of patients.

"Our findings will inspire new approaches for developing diagnostic tools and designing drugs, such as targeting PTM vulnerabilities to slow disease progression," said Dr. Fitzpatrick, who is also a member of Columbia's Taub Institute for Research on Alzheimer's Disease and the Aging Brain. "Neurodegenerative diseases are among the most complex and distressing class of illnesses, but through our work and that of our colleagues and collaborators, we are building a roadmap toward successful diagnostics and therapeutics."

This paper is titled "Posttranslational modifications mediate the structural diversity of tauopathy strains." Additional contributors include Yari Carlomagno, PhD, Duc Duong, Sean Kundinger, Kevin Wang, Dewight Williams, PhD, Michael DeTure, PhD, Dennis Dickson, MD, and Casey Cook, PhD.

This research was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke and National Institute on Aging (U01NS110438, RF1AG056151, R35NS097273, U01NS110438-02, P01NS084974, P01NS099114, R01NS088689, RF1AG062077-01, RF1 AG062171-01, U54NS100693, R01AG053960, R01AG061800, U01AG046161, U01AG061357, S10RR23057, S10OD018111, U24GM116792), NYSTAR and the NIH (GM103310), the National Science Foundation (MRI Grant 1531991, DBI-1338135, DMR-1548924), the Simons Foundation (349247), the Mayo Clinic Foundation, the Association for Frontotemporal Degeneration, the Dana Foundation and the Cure Alzheimer's Fund.

The authors report no financial or other conflicts of interest.

Columbia University'sMortimer B. Zuckerman Mind Brain Behavior Institutebrings together a group of world-class scientists and scholars to pursue the most urgent and exciting challenge of our time: understanding the brain and mind. A deeper understanding of the brain promises to transform human health and society. From effective treatments for disorders like Alzheimer's, Parkinson's, depression and autism to advances in fields as fundamental as computer science, economics, law, the arts and social policy, the potential for humanity is staggering. To learn more, visit:zuckermaninstitute.columbia.edu.

Contact:Anne Holden, anne.holden@columbia.edu,212.853.0171

View original content to download multimedia:http://www.prnewswire.com/news-releases/toxic-protein-linked-to-alzheimers-and-other-neurodegenerative-diseases-exposed-in-new-detail-300999642.html

SOURCE Columbia University's Zuckerman Institute

Go here to read the rest:
Toxic Protein, Linked to Alzheimer's and Other Neurodegenerative Diseases, Exposed in New Detail - P&T Community

Dyne Therapeutics Expands Leadership Team with Key Hires – Business Wire

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the addition of three key members to its leadership team: Oxana Beskrovnaya, Ph.D., senior vice president and head of research; Chris Mix, M.D., senior vice president, clinical development; and John Najim, vice president, chemistry, manufacturing and controls (CMC).

Dyne is establishing a leadership position in muscle disease therapeutics by combining transformative science with an organizational passion for changing the lives of patients, said Joshua Brumm, president and chief executive officer of Dyne. We are thrilled to welcome Oxana, Chris and John to our growing team. Leveraging their collective experience in the discovery and development of novel medicines, we are poised to rapidly advance our programs toward the clinic and are fully focused on execution.

Dr. Beskrovnaya is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. Prior to joining Dyne, she served as head of musculoskeletal and renal research in Sanofis rare disease and neurological unit, where she advanced a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins and small molecules. Dr. Beskrovnaya is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. She received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.

Dr. Mix brings extensive clinical development experience to Dyne, most recently serving as vice president of rare genetic disease clinical development at Agios Pharmaceuticals, where he oversaw development across several hemolytic anemia indications. In his previous role as vice president of clinical development at Sarepta Therapeutics, he focused on advancing candidate therapies for rare neuromuscular disease. Dr. Mix received his B.A. in chemistry from Haverford College and his M.D. from the University of Massachusetts Medical School. He completed his residency in internal medicine at Tufts Medical Center, a fellowship in nephrology at the Beth Israel Deaconess Medical Center in Boston and an M.S. in clinical care research at the Tufts School of Biomedical Sciences.

Mr. Najim brings a wealth of CMC biopharmaceutical development and cGMP manufacturing experience across multiple biologic expression systems and small molecules. Mr. Najim previously held roles of increasing responsibility at Proteon Therapeutics, including most recently as vice president of manufacturing and process development, and also served as associate director of manufacturing at Dyax Corporation. He received his B.S. in biochemistry from Merrimack College and his MBA from Bentley University.

About Dyne TherapeuticsDyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The companys FORCE platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit http://www.dyne-tx.com, and follow us on Twitter and LinkedIn.

Continued here:
Dyne Therapeutics Expands Leadership Team with Key Hires - Business Wire